Phase 2 trial of brentuximab vedotin for the treatment of anaplastic large cell lymphoma (ALCL) - ONA
Links shared publicly online about this topic.
- 806total visits
Phase 2 trial of brentuximab vedotin for the treatment of anaplastic large cell lymphoma (ALCL) - ONA
View full resource at oncologynurseadvisor.com
Tags: Genetic, Cancer, Lymphoma, Phase 2 Clinical Trial, Genetics
Most Recently Shared on October 12, 2010 at 7:53 pm By:
Phase 2 trial of brentuximab vedotin for the treatment of anaplastic large cell lymphoma… http://goo.gl/fb/E1Zk1
Seattle Genetics Announces Unanimous Recommendations from FDA Advisory Committee in Favor of Accelerated Approval of Adcetris for Post-Transplant Relapsed Hodgkin Lymphoma and Relapsed or Refractory Systemic ALCL
drugs.com — “Adcetris (brentuximab vedotin) is a new drug in development for the treatment of Hodgkin's lymphoma and anaplastic large cell lymphoma. Adcetris information includes news, clinical trial results and side effects.” View full resource at drugs.com
Most Recently Shared on July 15, 2011 at 11:14 pm By:
Drugs and Devices OW OW Health
Seattle Genetics Announces Unanimous Recommendations from FDA Advisory Committee in Favor of Accelerated A... http://bit.ly/n2iblP #drug
Phase 2 trial of brentuximab vedotin for the treatment of anaplastic large cell lymphoma (ALCL) - MPR
empr.com — “Seattle Genetics and Millennium, a wholly owned subsidiary of Takeda, announced results from its Phase 2 trial of brentuximab vedotin (SGN-35) for the treatment of relapsed or refractory systemic anaplastic large cell lymphoma (ALCL).” View full resource at empr.com
Most Recently Shared on October 12, 2010 at 7:25 pm By:
MPR News: Phase 2 trial of brentuximab vedotin for the treatment of anaplastic large cell lymphoma (ALCL): Seattle... http://bit.ly/duAZjo
Advertisement
